Search Results - "Marth C"

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Authors: Harter, P. Marth, C. Mouret-Reynier, M.-A. et al.

Source: Annals of Oncology. Feb2025, Vol. 36 Issue 2, p185-196. 12p.

1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.

Authors: Marth, C. Lorusso, D. Bidzinski, M. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS748-S749. 2p.

Mechanism of Wittig reaction: evidence against betaine intermediates.

Authors: Vedejs, E. Marth, C. F.

Source: Journal of the American Chemical Society; May 9 1990, Vol. 112, p3905-3909, 5p

Substituent effects and the Wittig mechanism: the case for stereospecific oxaphosphetane decomposition.

Authors: Vedejs, E. Marth, C. F. Ruggeri, R.

Source: Journal of the American Chemical Society; June 8 1988, Vol. 110, p3940-3948, 9p

Mechanism of the Wittig reaction: the role of substituents at phosphorus.

Authors: Vedejs, E. Marth, C. F.

Source: Journal of the American Chemical Society; June 8 1988, Vol. 110, p3948-3958, 11p

Fiber fineness (Micronaire), neps in card web, and yarn appearance grades.

Authors: Marth, C. T.

Source: Textile Research Journal; September 1952, Vol. 22, p561-566, 6p

Global-Local Algebraic Quantization of a Two-Dimensional Non-Hermitian Potential.

Authors: Vrinceanu, D. Marth, C. Handy, C.

Source: International Journal of Theoretical Physics. Nov2015, Vol. 54 Issue 11, p4005-4010. 6p.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Authors: Wagner, U Marth, C Largillier, R et al.

Source: British Journal of Cancer. 8/7/2012, Vol. 107 Issue 4, p588-591. 4p. 4 Charts, 1 Graph.

Industrial Sales Force Selection: Current Knowledge and Needed Research.

Authors: Johnston, Wesley J. Cooper, Marth C.

Source: Journal of Personal Selling & Sales Management. Spring/Summer81, Vol. 1 Issue 2, p49. 9p.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Authors: Marth, C. Reimer, D. Zeimet, A. G.

Source: Annals of Oncology. 2017 Supplement, Vol. 28, p36-39. 4p. 1 Diagram.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: Marth, C. Landoni, F. Mahner, S. et al.

Source: Annals of Oncology. 2017 Supplement, Vol. 28, piv72-iv83. 12p. 1 Diagram, 6 Charts.

Why did p53 gene therapy fail in ovarian cancer?

Authors: Zeimet AG Marth C Zeimet, Alain G et al.

Source: Lancet Oncology. Jul2003, Vol. 4 Issue 7, p415-422. 8p.

Circulating tumor cells in metastatic breast cancer -- toward individualized treatment?

Authors: Braun S Marth C

Source: New England Journal of Medicine. 8/19/2004, Vol. 351 Issue 8, p824-826. 3p.

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.

Authors: Sehouli, J Reinthaller, A Marth, C et al.

Source: British Journal of Cancer. 10/14/2014, Vol. 111 Issue 8, p1519-1525. 7p. 1 Diagram, 3 Charts.

1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001.

Authors: Akıllı, H. Moore, R.G. Marth, C. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS741-S741. 1p.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: Marth, C Landoni, F Mahner, S et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, piv262-iv262. 1p.

Immune cells in colorectal cancer.

Authors: Wolf D Marth C Wolf AM et al.

Source: New England Journal of Medicine. 4/6/2006, Vol. 354 Issue 14, p1531-1532. 2p.

Secondary leukaemias after etoposide.

Authors: Zeimet, A G Thaler, J Abfalter, E et al.

Source: Lancet. 8/8/1992, Vol. 340 Issue 8815, p379-380. 2p.

Subjects: Adenocarcinoma, Antineoplastic agents, Etoposide, Lymphoblastic leukemia, Ovarian tumors, Acute myeloid leukemia

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Authors: Ray-Coquard, I. Leary, A. Pignata, S. et al.

Source: Annals of Oncology. Aug2023, Vol. 34 Issue 8, p681-692. 12p.

Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.

Authors: Ray-Coquard, I. Cropet, C. Harter, P. et al.

Source: Annals of Oncology. Oct2025, Vol. 36 Issue 10, p1221-1222. 2p.